

Amendments to the Specification:

Please replace the paragraph on page 1 under "Cross-Reference to Related Applications" with the following amended paragraph:

This application claims priority from is a continuation-in-part of U.S. Patent Application Serial No. 09/249,700, filed February 12, 1999, which claims the benefits benefit of provisional application U.S. Serial No. 60/077,133, filed March 6, 1998, under 35 U.S.C. section 119(e).

Please replace the paragraph on page 4, lines 10-16 with the following amended paragraph:

In preferred embodiments, the inner wall comprises a member selected from the group consisting of hydrogel polymers, osmopolymers, osmotically-effective compounds, suspending agents, compounds for forming passageway, pore formers polypeptides, proteins, polysaccharides, cellulose derivatives, surfactants, synthetic polymers and inorganic polymers. More preferably, the membrane system comprises a hydrophobic substance comprising ethyl acetate ethylcellulose or cellulose acetate; a hydrophobic membrane comprising hydroxyalkylcellulose; and a semipermeable substance comprising cellulose acetate.

Please replace the paragraph on page 5, lines 13-20 with the following amended paragraph:

Another objective of the invention is to provide a controlled release dosage form, wherein said inner wall comprises a member selected from the group consisting of hydrogel polymers, osmopolymers, osmotically effective compounds, suspending agents, compounds for forming passageway, pore formers polypeptides, proteins, polysaccharides, cellulose derivatives, surfactants, synthetic polymers and inorganic polymers. In a preferred embodiment, the controlled release dosage form comprises a hydrophobic substance comprising ethyl acetate ethylcellulose or cellulose acetate; a hydrophobic membrane comprising hydroxyalkylcellulose; and a semipermeable substance comprising cellulose acetate.

Please replace the paragraph starting on page 15, line 19 with the following amended paragraph:

Dosage form 10, in compartment 15 comprises a pharmaceutically acceptable polymer hydrogel 18, as represented by horizontal dashes. Representative polymer hydrogels comprise a

maltodextrin polymer comprising the formula $(C_6H_{12}O_5)_\lambda \cdot H_2O$, wherein λ is 3 to 7,500, and the maltodextrin polymer comprises a 500 to 1,250,000 number-average molecular weight; a poly(alkylene oxide) represented by poly(ethylene oxide) and poly(propylene oxide) having a 50,000 to 750,000 weight-average molecular weight, and more specifically represented by a poly(ethylene oxide) of at least one of 100,000, 200,000, 300,000, or 400,000 weight-average molecular weights; an alkali carboxyalkylcellulose, wherein the alkali is sodium, lithium, potassium or calcium, and alkyl is 1 to 5 carbons such as methyl, ethyl, propyl or butyl of 10,000 to 175,000 weight-average molecular weight; and ~~a copolymer of ethylene acrylic acid acrylate copolymers~~, including methacrylic and ethacrylic acid of 10,000 to 1,500,000 number-average molecular weight. The therapeutic composition comprises 5 to 400 mg of a polymer hydrogel. The therapeutic composition can be manufactured into dosage form 10 and it can be used as the therapeutic composition for its therapeutic effect. The hydrogel polymer exhibits an osmotic pressure gradient across bilayer interior wall and exterior wall thereby imbibing fluid into compartment 15 to form a solution or a suspension comprising drug 14 that is hydrodynamically and osmotically delivered through a passageway from dosage form 10.

Please replace the paragraph on page 19, lines 3-11 with the following amended paragraph:

Push layer 22 comprises 0 to 5 mg of a nontoxic colorant, or dye 26 identified by a half-circle. The colorant 26 makes the dosage form more esthetic in appearance, and it serves to identify the dosage form during manufacture and during therapy. The colorants include Food and Drug Administrations Colorant (FD&C), such as FD&C No. 1 blue dye, FD&C No. 4 red dye, FD&C yellow No. 5, FD&C yellow No. 6, FD&C blue No. 2, FD&C green No. 3, FD&C cranberry red No. 40, red ferric oxide, yellow ferric oxide, black ferric oxide, titanium dioxide, carbon black, Opadry® comprising polycellulose polydexrin, or starch, or cured polymers with dyes commercially available from Colorcon Corporation, West Point, Pennsylvania; erythrosine, allura red, sunset yellow and chlorophylls.